Approaching patients with a ‘genotype-first’ technique could help us to better understand genetic diseases and to develop faster, more accurate diagnostics.
Efficiently translating genomic research into the clinic is one of the most important steps in the development of the field. The clinic is where we will see things come to fruition.
The FDA said yesterday it will relax its review of some genetic tests that examine millions of different variants at the same time, and finalised two guidances designed to enhance collaboration among researchers, and drive the efficient development of novel NGS-based tests.
A literature review finds an increased risk of cancer, late-stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.
Researchers have proposed a radical change in the way Alzheimer’s disease is defined, focusing on biological changes in the body, rather than clinical symptoms such as memory loss and cognitive decline.
23andMe CEO and co-founder Anne Wojcicki says consumers don’t need experts to interpret results from genetic risk tests, and compared the information her company offers to at-home pregnancy tests. But is it that simple?
There is, as of yet, no cure for Alzheimer’s, but a new blood test could open the door to new avenues in drug discovery.
Concerningly, 20% of publicly funded cancer clinical trials in the United States fail because investigators are unable to enroll enough participants.
Studies carried out at Emory University have shown that DNA methylation patterns in saliva appear to be more similar to patterns from the brain, than methylation in blood. Researcher Alicia Smith Associate Professor and Vice Chair for Research, Gynecology and Obstetrics at Emory University joins the discussion.
Dr Joan O’Brien, chair of the University of Pennsylvania’s Department of Ophthalmology, Scheie Eye Institute, Philadelphia, and primary investigator of POAAGG, joins our panel of experts on April 10th to discuss bias in genetic studies and what is being done to remove it.
Access to electronic patient data has huge potential, and with the federal Centers for Medicare and Medicaid Services calling for entry, we could soon be seeing the impact in the healthcare system.
Our panel of experts come together to discuss the benefits and drawbacks on the use of saliva DNA in genetic studies and how it’s currently being used to diminish biases in our databases and uncovering the role of epigenetics in psychiatric disorders.